{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T05:22:32Z","timestamp":1751347352237},"reference-count":23,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2016,11,1]],"date-time":"2016-11-01T00:00:00Z","timestamp":1477958400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","lipidjournal.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Clinical Lipidology"],"published-print":{"date-parts":[[2016,11]]},"DOI":"10.1016\/j.jacl.2016.09.001","type":"journal-article","created":{"date-parts":[[2016,9,14]],"date-time":"2016-09-14T17:45:31Z","timestamp":1473875131000},"page":"1481-1487","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["LDL apheresis activates the complement system and the cytokine network, whereas PCSK9 inhibition with evolocumab induces no inflammatory response"],"prefix":"10.1016","volume":"10","author":[{"given":"Knut Tore","family":"Lappeg\u00e5rd","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Terje","family":"Enebakk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hilde","family":"Thunhaug","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Judith Krey","family":"Ludviksen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tom Eirik","family":"Mollnes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anders","family":"Hovland","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jacl.2016.09.001_bib1","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.1161\/CIR.0000000000000297","article-title":"The Agenda for Familial Hypercholesterolemia: A Scientific Statement From the American Heart Association","volume":"132","author":"Gidding","year":"2015","journal-title":"Circulation"},{"key":"10.1016\/j.jacl.2016.09.001_bib2","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.ecl.2015.09.003","article-title":"Lipoprotein apheresis","volume":"45","author":"Moriarty","year":"2016","journal-title":"Endocrinol Metab Clin North Am"},{"key":"10.1016\/j.jacl.2016.09.001_bib3","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1002\/jca.20223","article-title":"Different inflammatory responses induced by three LDL-lowering apheresis columns","volume":"24","author":"Hovland","year":"2009","journal-title":"J Clin Apher"},{"key":"10.1016\/j.jacl.2016.09.001_bib4","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1016\/j.atherosclerosis.2015.05.038","article-title":"The complement system and toll-like receptors as integrated players in the pathophysiology of atherosclerosis","volume":"241","author":"Hovland","year":"2015","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.jacl.2016.09.001_bib5","doi-asserted-by":"crossref","first-page":"3831","DOI":"10.4049\/jimmunol.1203487","article-title":"Complement in immune and inflammatory disorders: Pathophysiological mechanisms","volume":"190","author":"Ricklin","year":"2013","journal-title":"J Immunol"},{"key":"10.1016\/j.jacl.2016.09.001_bib6","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa1316222","article-title":"A 52-week placebo-controlled trial of evolocumab in hyperlipidemia","volume":"370","author":"Blom","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacl.2016.09.001_bib7","doi-asserted-by":"crossref","first-page":"2415","DOI":"10.1093\/eurheartj\/ehv174","article-title":"PCSK9 (Proprotein convertase subtilisin\/kexin type 9) inhibitors: past, present, and the future","volume":"36","author":"Shimada","year":"2015","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacl.2016.09.001_bib8","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1056\/NEJMoa1500858","article-title":"Efficacy and safety of evolocumab in reducing lipids and cardiovascular events","volume":"372","author":"Sabatine","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacl.2016.09.001_bib9","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.atherosclerosis.2016.06.015","article-title":"Transition from LDL apheresis to evolocumab in heterozygous FH is equally effective in lowering LDL, without lowering HDL cholesterol","volume":"251","author":"Lappeg\u00e5rd","year":"2016","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.jacl.2016.09.001_bib10","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/j.molimm.2013.05.221","article-title":"An international serum standard for application in assays to detect human complement activation products","volume":"56","author":"Bergseth","year":"2013","journal-title":"Mol Immunol"},{"key":"10.1016\/j.jacl.2016.09.001_bib11","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/0167-5699(87)90167-8","article-title":"Separation of self from non-self in the complement system","volume":"8","author":"Atkinson","year":"1987","journal-title":"Immunol Today"},{"key":"10.1016\/j.jacl.2016.09.001_bib12","doi-asserted-by":"crossref","first-page":"2735","DOI":"10.15252\/embj.201591881","article-title":"Complement activation, regulation, and molecular basis for complement-related diseases","volume":"34","author":"Bajic","year":"2015","journal-title":"EMBO J"},{"key":"10.1016\/j.jacl.2016.09.001_bib13","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1111\/j.1365-2249.2004.02627.x","article-title":"The quantitative role of alternative pathway amplification in classical pathway induced terminal complement activation","volume":"138","author":"Harboe","year":"2004","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.jacl.2016.09.001_bib14","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1111\/j.1365-2249.2006.03072.x","article-title":"Design of a complement mannose-binding lectin pathway-specific activation system applicable at low serum dilutions","volume":"144","author":"Harboe","year":"2006","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.jacl.2016.09.001_bib15","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1111\/j.1365-3083.1993.tb02564.x","article-title":"Modification of the complement binding properties of polystyrene: effects of end-point heparin attachment","volume":"37","author":"Nilsson","year":"1993","journal-title":"Scand J Immunol"},{"key":"10.1016\/j.jacl.2016.09.001_bib16","doi-asserted-by":"crossref","first-page":"2288","DOI":"10.1016\/j.actbio.2012.02.017","article-title":"Complement profile and activation mechanisms by different LDL apheresis systems","volume":"8","author":"Hovland","year":"2012","journal-title":"Acta Biomater"},{"key":"10.1016\/j.jacl.2016.09.001_bib17","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.molimm.2014.06.036","article-title":"A vital role for complement in heart disease","volume":"61","author":"Lappeg\u00e5rd","year":"2014","journal-title":"Mol Immunol"},{"key":"10.1016\/j.jacl.2016.09.001_bib18","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1038\/nature08938","article-title":"NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals","volume":"464","author":"Duewell","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.jacl.2016.09.001_bib19","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1016\/j.imbio.2014.06.006","article-title":"Cholesterol crystal-induced endothelial cell activation is complement-dependent and mediated by TNF","volume":"219","author":"Nymo","year":"2014","journal-title":"Immunobiology"},{"key":"10.1016\/j.jacl.2016.09.001_bib20","doi-asserted-by":"crossref","first-page":"2837","DOI":"10.4049\/jimmunol.1302484","article-title":"Cholesterol crystals induce complement-dependent inflammasome activation and cytokine release","volume":"192","author":"Samstad","year":"2014","journal-title":"J Immunol"},{"key":"10.1016\/j.jacl.2016.09.001_bib21","doi-asserted-by":"crossref","first-page":"e0120633","DOI":"10.1371\/journal.pone.0120633","article-title":"Serum levels of monocyte chemoattractant protein-1 and all-cause and cardiovascular mortality among patients with coronary artery disease","volume":"10","author":"Ding","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.jacl.2016.09.001_bib22","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1038\/nri3345","article-title":"Thrombosis as an intravascular effector of innate immunity","volume":"13","author":"Engelmann","year":"2013","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.jacl.2016.09.001_bib23","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1016\/j.amjcard.2007.06.033","article-title":"Effect of low-density lipoprotein apheresis on inflammatory and noninflammatory high-density lipoprotein cholesterol","volume":"100","author":"Opole","year":"2007","journal-title":"Am J Cardiol"}],"container-title":["Journal of Clinical Lipidology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1933287416303312?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1933287416303312?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,8]],"date-time":"2018-09-08T12:58:49Z","timestamp":1536411529000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1933287416303312"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,11]]},"references-count":23,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2016,11]]}},"alternative-id":["S1933287416303312"],"URL":"https:\/\/doi.org\/10.1016\/j.jacl.2016.09.001","relation":{},"ISSN":["1933-2874"],"issn-type":[{"value":"1933-2874","type":"print"}],"subject":[],"published":{"date-parts":[[2016,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"LDL apheresis activates the complement system and the cytokine network, whereas PCSK9 inhibition with evolocumab induces no inflammatory response","name":"articletitle","label":"Article Title"},{"value":"Journal of Clinical Lipidology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacl.2016.09.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 National Lipid Association. All rights reserved.","name":"copyright","label":"Copyright"}]}}